How Are Bone and Soft Tissue Tumors Treated?
Treatment for bone and soft tissue tumours is planned around the specific tumour type, its grade and stage, and where it sits in the body. Most patients are treated by a multidisciplinary team at a specialist sarcoma centre, and the core options are surgery, chemotherapy, radiotherapy, and newer systemic or targeted therapies — often used in combination rather than alone. The sections below explain what each option does, how the sequence is decided, and what to expect during and after treatment.
The main treatment options
Surgery
Surgery is the mainstay of treatment for most bone and soft tissue tumours, and for many patients it is the only treatment needed. The goal is usually wide local excision: removing the tumour together with a margin of normal tissue around it, so that no tumour cells are left behind.
- Limb-sparing surgery removes the tumour while preserving the affected arm or leg. It is possible for many patients and is generally preferred when a safe margin can be achieved.
- Amputation is reserved for tumours where limb-sparing surgery cannot remove the tumour safely, or where the limb would not function afterwards.
- Reconstruction may follow removal of bone: options include metal prostheses, bone grafts, or other implants. The choice depends on the tumour's location, the patient's age, and how much bone was removed.
Chemotherapy
Chemotherapy uses drugs that travel through the bloodstream to kill tumour cells. In musculo-skeletal oncology it is used mainly for:
- Certain bone tumours, such as osteosarcoma and Ewing sarcoma, where it is a standard part of treatment.
- Some high-grade soft tissue sarcomas, particularly those at higher risk of spreading.
- Advanced or metastatic disease, to control tumour growth.
Chemotherapy is usually given as a series of cycles over several months, with rest periods in between.
Radiotherapy
Radiotherapy uses high-energy radiation to damage tumour cells. It is used more often for soft tissue sarcomas than for bone tumours, and can be given:
- Before surgery to shrink a tumour and make it easier to remove.
- After surgery when the margin is close or uncertain, to reduce the risk of local recurrence.
- As the main treatment when surgery is not possible or would cause unacceptable damage.
- For symptom relief in advanced disease.
Targeted and other systemic therapies
Beyond conventional chemotherapy, treatment may include drugs that act on specific molecular features of a tumour, or other systemic agents. Whether these are appropriate depends on the tumour's subtype and biology, and they are typically considered within specialist or trial settings.
How a treatment plan is decided
No single factor determines treatment. The team weighs several things together:
| Factor | Why it matters |
|---|---|
| Tumour type | Bone and soft tissue tumours include many distinct diseases with different standard treatments |
| Grade | High-grade tumours grow faster and are more likely to spread, which usually means more intensive treatment |
| Stage | Whether the tumour is localised or has spread changes the goal of treatment |
| Location | Tumours near nerves, blood vessels, or joints are harder to remove with a safe margin |
| Patient factors | Age, general health, and preferences affect what can be tolerated |
This is why treatment for the same named tumour can differ between two patients.
The role of the multidisciplinary team and specialist centres
A multidisciplinary team (MDT) brings together surgeons, medical and radiation oncologists, radiologists, pathologists, and specialist nurses to agree on a plan. Because these tumours are rare and their treatment is complex, guidance consistently points to management in specialist sarcoma centres, where teams see enough cases to make reliable judgements about margins, reconstruction, and systemic therapy.
The European Musculo-Skeletal Oncology Society (EMSOS) exists to advance the science and practice of diagnosing and treating bone and soft tissue tumours and to promote a common high standard of musculo-skeletal oncology across Europe — a reflection of how central specialist, team-based care is to this field.
Typical treatment sequences
Treatment is often described by where it sits relative to surgery:
- Neoadjuvant therapy — chemotherapy or radiotherapy given before surgery. It may shrink the tumour, make surgery easier, and in some tumours allows the response to treatment to be assessed.
- Adjuvant therapy — chemotherapy or radiotherapy given after surgery to reduce the risk of the tumour returning or spreading.
- Definitive or palliative treatment — when surgery is not the main approach, systemic therapy or radiotherapy may be used to control the disease or relieve symptoms.
Not every patient needs every step. Some are treated with surgery alone; others receive several treatments in sequence.
What to expect during and after treatment
- During treatment, expect regular imaging and clinical reviews to check how the tumour is responding and to catch complications early. Side effects depend on the treatment type and are managed by the care team.
- After treatment, follow-up usually continues for several years, with imaging and clinic visits at intervals. Follow-up looks for recurrence, spread, and late effects of treatment.
- Rehabilitation is often a major part of recovery, especially after limb-sparing surgery or amputation. Physiotherapy and, where needed, prosthetics or occupational therapy help restore function.
Questions to ask your care team
- What type and grade is my tumour, and what stage is it?
- Is surgery possible, and can it be limb-sparing?
- Do I need chemotherapy or radiotherapy, and if so, before or after surgery?
- What are the expected benefits and risks of each option?
- Is my case being discussed by a multidisciplinary team, and is it being managed at a specialist sarcoma centre?
- What follow-up and rehabilitation will I need?
The answers to these questions are what turn a general description of treatment into a plan for a specific patient.